ENTPD1 and cancer: In fact, p53 mutant DNA [196] and ENTPD1 high RNA expression [197] have been identified as relevant immune response biomarkers to Vigil® sensitivity and may further contribute to the induction of a “hot” tumor microenvironment and greater immune responsiveness to the clonal neoantigens that contain the appropriate epitopes for TCR binding and enabling a robust anti-cancer immune response.